{"url_path":"/sec/atxi/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1644963/0001437749-26-015759-index.html","accession_number":"0001437749-26-015759","cik":"0001644963","ticker":"ATXI","issuer_name":"AVENUE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1644963/0001437749-26-015759-index.html","primary_entity_key":"0001644963","primary_entity_name":"AVENUE THERAPEUTICS, INC."},"word_count":632,"has_tables":true,"body_markdown":"atxi20260331_10q.htm\n\n0001644963\nAVENUE THERAPEUTICS, INC.\nfalse\n--12-31\nQ1\n2026\n\n0.0001\n0.0001\n2,000,000\n2,000,000\n250,000\n250,000\n250,000\n250,000\n0\n0\n0.0001\n0.0001\n200,000,000\n200,000,000\n3,294,967\n3,294,967\n3,183,558\n3,183,558\n104,432\n1,178\n1\n1\nfalse\nfalse\nfalse\nfalse\nClass A preferred shares are presented on an as-if converted basis.\n\n00016449632026-01-012026-03-31\nxbrli:shares\n00016449632026-05-06\nthunderdome:item\niso4217:USD\n00016449632026-03-31\n00016449632025-12-31\n0001644963us-gaap:NonrelatedPartyMember2026-03-31\n0001644963us-gaap:NonrelatedPartyMember2025-12-31\n0001644963us-gaap:RelatedPartyMember2026-03-31\n0001644963us-gaap:RelatedPartyMember2025-12-31\niso4217:USDxbrli:shares\n00016449632025-01-012025-03-31\n0001644963us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2025-12-31\n0001644963us-gaap:CommonStockMember2025-12-31\n0001644963us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001644963us-gaap:RetainedEarningsMember2025-12-31\n0001644963us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2026-01-012026-03-31\n0001644963us-gaap:CommonStockMember2026-01-012026-03-31\n0001644963us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001644963us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001644963us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2026-03-31\n0001644963us-gaap:CommonStockMember2026-03-31\n0001644963us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001644963us-gaap:RetainedEarningsMember2026-03-31\n0001644963us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2024-12-31\n0001644963us-gaap:CommonStockMember2024-12-31\n0001644963us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001644963us-gaap:RetainedEarningsMember2024-12-31\n0001644963us-gaap:NoncontrollingInterestMember2024-12-31\n00016449632024-12-31\n0001644963us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2025-01-012025-03-31\n0001644963us-gaap:CommonStockMember2025-01-012025-03-31\n0001644963us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001644963us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001644963us-gaap:NoncontrollingInterestMember2025-01-012025-03-31\n0001644963us-gaap:PreferredClassAMemberus-gaap:PreferredStockMemberatxi:ATMAgreementMember2025-01-012025-03-31\n0001644963us-gaap:CommonStockMemberatxi:ATMAgreementMember2025-01-012025-03-31\n0001644963us-gaap:AdditionalPaidInCapitalMemberatxi:ATMAgreementMember2025-01-012025-03-31\n0001644963us-gaap:RetainedEarningsMemberatxi:ATMAgreementMember2025-01-012025-03-31\n0001644963us-gaap:NoncontrollingInterestMemberatxi:ATMAgreementMember2025-01-012025-03-31\n0001644963atxi:ATMAgreementMember2025-01-012025-03-31\n0001644963us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2025-03-31\n0001644963us-gaap:CommonStockMember2025-03-31\n0001644963us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001644963us-gaap:RetainedEarningsMember2025-03-31\n0001644963us-gaap:NoncontrollingInterestMember2025-03-31\n00016449632025-03-31\n0001644963us-gaap:NonrelatedPartyMember2026-01-012026-03-31\n0001644963us-gaap:NonrelatedPartyMember2025-01-012025-03-31\n0001644963us-gaap:RelatedPartyMember2026-01-012026-03-31\n0001644963us-gaap:RelatedPartyMember2025-01-012025-03-31\nxbrli:pure\n0001644963us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-31\n0001644963us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-31\n0001644963atxi:DeferredRestrictedStockUnitsMember2026-01-012026-03-31\n0001644963atxi:DeferredRestrictedStockUnitsMember2025-01-012025-03-31\n0001644963us-gaap:WarrantMember2026-01-012026-03-31\n0001644963us-gaap:WarrantMember2025-01-012025-03-31\n0001644963us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001644963us-gaap:EmployeeStockOptionMember2025-01-012025-03-31\n0001644963atxi:ClassAPreferredSharesMember2026-01-012026-03-31\n0001644963atxi:ClassAPreferredSharesMember2025-01-012025-03-31\n0001644963atxi:DukeUniversityMemberatxi:Atx04Member2026-02-012026-02-28\n0001644963atxi:DukeUniversityMemberatxi:Atx04Member2026-02-28\n0001644963atxi:FortressBiotechIncMemberatxi:IvTramadolMember2015-02-172015-02-17\n0001644963atxi:AdditionalPaymentMemberatxi:FortressBiotechIncMemberatxi:IvTramadolMember2015-02-172015-06-17\n0001644963atxi:RevogenexLicenseMember2015-06-17\n0001644963atxi:PolpharmaMember2018-10-292018-10-29\n0001644963atxi:AnnjiMember2025-04-242025-04-24\n0001644963atxi:AnnjiMember2025-04-24\n0001644963atxi:AnnjiMembersrt:MaximumMember2025-04-24\n0001644963atxi:ManagementServicesAgreementMemberatxi:FortressMember2025-02-012025-02-28\n0001644963atxi:ManagementServicesAgreementMemberatxi:FortressMember2026-01-012026-03-31\n0001644963atxi:ManagementServicesAgreementMemberatxi:FortressMember2025-01-012025-03-31\n0001644963atxi:FortressMember2015-02-28\n0001644963atxi:FortressMember2026-01-012026-01-01\n0001644963atxi:BaergicbioIncMemberatxi:FoundersAgreementAndManagementServicesAgreementMember2022-11-08\n0001644963atxi:BaergicbioIncMemberatxi:FoundersAgreementAndManagementServicesAgreementMember2025-01-012025-12-31\n0001644963atxi:BaergicbioIncMemberatxi:FoundersAgreementAndManagementServicesAgreementMember2025-01-012025-03-31\n0001644963atxi:BaergicbioIncMemberatxi:FoundersAgreementAndManagementServicesAgreementMember2025-03-31\n0001644963atxi:BaergicbioIncMemberatxi:FoundersAgreementAndManagementServicesAgreementMember2022-12-31\n0001644963atxi:BaergicbioIncMemberatxi:AvenueBaergicFoundersAgreementMember2022-12-31\n0001644963atxi:BaergicbioIncMemberatxi:AvenueBaergicFoundersAgreementMember2017-03-092017-03-09\n0001644963atxi:FortressMemberatxi:AvenueBaergicFoundersAgreementMember2017-03-09\n00016449632016-09-13\n0001644963us-gaap:PreferredClassAMember2016-09-13\n0001644963us-gaap:PreferredClassAMember2019-09-13\n0001644963us-gaap:PreferredClassAMember2022-09-22\n00016449632024-05-10\n0001644963atxi:ATMAgreementMember2024-05-102024-05-10\n0001644963atxi:TwoThousandFifteenIncentivePlanMember2021-12-31\n0001644963us-gaap:ShareBasedPaymentArrangementNonemployeeMemberatxi:TwoThousandFifteenIncentivePlanMembersrt:MaximumMember2023-01-30\n0001644963atxi:TwoThousandFifteenIncentivePlanMember2024-06-24\n0001644963atxi:IncentiveStockOptionsMemberatxi:TwoThousandFifteenIncentivePlanMembersrt:MaximumMember2024-06-24\n0001644963us-gaap:ShareBasedPaymentArrangementNonemployeeMemberatxi:TwoThousandFifteenIncentivePlanMembersrt:MaximumMember2024-06-24\nutr:Y\n0001644963atxi:TwoThousandFifteenIncentivePlanMember2024-06-242024-06-24\n0001644963atxi:TwoThousandFifteenIncentivePlanMember2026-03-31\n0001644963us-gaap:RestrictedStockUnitsRSUMember2026-03-31\n0001644963us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-31\n0001644963atxi:DeferredRestrictedStockUnitsMember2026-03-31\n00016449632025-01-012025-12-31\n0001644963us-gaap:EmployeeStockOptionMember2026-03-31\n0001644963us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001644963atxi:ResearchAndDevelopmentMember2026-01-012026-03-31\n0001644963atxi:ResearchAndDevelopmentMember2025-01-012025-03-31\n0001644963atxi:GeneralAndAdministrativeMember2026-01-012026-03-31\n0001644963atxi:GeneralAndAdministrativeMember2025-01-012025-03-31\n0001644963atxi:InvagenPharmaceuticalsIncMember2023-02-032023-02-03\n0001644963atxi:InvagenPharmaceuticalsIncMember2023-02-03\n0001644963atxi:InvagenPharmaceuticalsIncMember2025-01-012025-03-31\n0001644963atxi:InvagenPharmaceuticalsIncMember2026-01-012026-03-31\n0001644963atxi:InvagenPharmaceuticalsIncMember2023-02-032026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001644963atxi:October2022WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2026-01-012026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputSharePriceMember2026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputSharePriceMember2025-12-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-12-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-12-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-31\n0001644963atxi:October2022WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-12-31\n\n \n\n \n\n[Table of Contents](#toc)\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM** **10-Q**\n\n \n\n**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the transition period from**          **to**\n\n \n\n**Commission File Number** ******001**-**38114******\n\n \n\n**AVENUE THERAPEUTICS,** **INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n\n**47-4113275**\n\n(State or other jurisdiction of incorporation or organization)\n\n(I.R.S. Employer Identification No.)\n\n \n\n**1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154**\n\n(Address of principal executive offices and zip code)\n\n \n\n**(781)****652**‑**4500******\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Exchange Act: None\n\n \n\nSecurities registered pursuant to Section 12(g) of the Exchange Act:\n\n \n\n**Title of Class**\n\n**Trading Symbol(s)**\n\nCommon Stock\n\nATXI (OTC Markets Group, Inc.)\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   ☒   No  ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes   ☒   No  ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer  ☐\n\nAccelerated filer  ☐\n\nNon-accelerated filer    ☒\n\nSmaller reporting company  ☒\n\nEmerging growth company ☐\n \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes  ☐   No  ☒\n\n \n\nIndicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.\n\n \n\nClass of Common Stock\n \nOutstanding Shares as of May 6, 2026\n\nCommon Stock, $0.0001 par value\n \n3,294,967\n\n \n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\n \n\n \n\n**AVENUE THERAPEUTICS,** **INC.**\n\n**Form** **10**‑**Q**\n\n**For the Quarter Ended March 31, 2026**\n\n \n\n**Table of Contents**\n\n \n\n \n \n\n**Page** **No.**\n\n[**PART** **I. FINANCIAL INFORMATION**](#bs)"}